Five stocks stand out heading into Wednesday, September 16, 2026, each carrying a bullish rating change issued on Tuesday, September 15. The Federal Open Market Committee held the federal funds target range at 3.50% to 3.75% at its July 29 meeting, and the CME Group FedWatch tool still prices roughly an 80% probability that policy rates hold steady through the balance of 2026.
The five ideas below span pharmaceutical mega-caps, digital media, artisan e-commerce, medical devices, and energy pipelines. Editorial notes only, not investment advice.
Eli Lilly (LLY) – Berenberg Turns Bullish on GLP-1 Franchise
Pharmaceutical mega-cap Eli Lilly was upgraded from Hold to Buy on Tuesday by Berenberg analyst Kerry Holford. The thesis focuses on the GLP-1 franchise (Mounjaro and Zepbound) extending manufacturing capacity as supply-constraint concerns ease, oral GLP-1 candidate orforglipron progressing toward regulatory submission on strong late-stage data, and the Alzheimer's therapy Kisunla contributing incremental commercial revenue as launch execution firms.
Shares traded near $1,137.54 during Tuesday's session, essentially flat, giving Eli Lilly a market capitalization near $1.07 trillion. The 52-week range of $712.05 to $1,292.65 shows the stock trading in the upper half of the year's range. The trailing price-to-earnings multiple sits at 38.18, and the dividend yield sits near 1%.
Consensus reads strong buy on the broader panel. Twenty sell-side firms cover the name with 18 bullish, one neutral, and one bearish. The average price target of $1,307.10 implies roughly 15% upside from Tuesday's level, and the panel high sits at $1,600.
Risks: The panel is not fully aligned. HSBC's Rajesh Kumar maintained Reduce at $940 on September 10 (target raised from $850 but still bearish), and Berenberg's own downgrade to Hold in September 2025 preceded Tuesday's reversal. GLP-1 manufacturing-capacity ramp, orforglipron commercial reception, and competitive dynamics against Novo Nordisk all remain factors to monitor.
New York Times (NYT) – Guggenheim Turns Bullish on Subscription Bundle
Digital media and subscription publisher New York Times was upgraded from Neutral to Buy on Tuesday by Guggenheim analyst Curry Baker, who raised his price target to $82 from $70. The thesis focuses on subscription bundle (news, Games, Cooking, Wirecutter, The Athletic) driving average revenue per user expansion, digital-advertising revenue benefiting from first-party-data advantages amid cookie deprecation, and licensing revenue emerging from AI-content-partnership agreements.
Shares traded near $73.04 during Tuesday's session, up about 3.84% on the upgrade catalyst, giving New York Times a market capitalization near $12 billion. The 52-week range of $54.10 to $87.10 shows the stock trading in the middle of the year's range. The trailing price-to-earnings multiple sits at 30.43, and the dividend yield sits near 1%.
Consensus reads buy on the broader panel. Seven sell-side firms cover the name with four bullish and three neutral. The average price target of $78.29 implies modest upside from Tuesday's level, and Citigroup's Jason Bazinet sits near the high at $94.
Risks: The panel is not uniformly aligned. Barclays' Kannan Venkateshwar maintained Equal-Weight at $63 on August 6, and B of A Securities' David Plaus carried Neutral at $80 on June 24. Subscription bundle attach-rate durability, digital-advertising trajectory, and AI-content-licensing pace all remain factors to monitor.
Etsy (ETSY) – Oppenheimer Turns Bullish on E-Commerce Recovery
Artisan e-commerce marketplace Etsy was upgraded from Perform to Outperform on Tuesday by Oppenheimer. The thesis focuses on gross-merchandise-sales returning to growth as buyer-frequency initiatives take hold, Depop and Reverb marketplace segments contributing accretive growth alongside the core marketplace, and take-rate expansion from Etsy Ads and merchandising services improving unit economics.
Shares traded near $74.08 during Tuesday's session, down about 0.51%, giving Etsy a market capitalization near $7 billion. The 52-week range of $44 to $87.97 shows the stock trading in the upper half of the year's range after a strong summer recovery. The trailing price-to-earnings multiple sits at 40.49.
Consensus reads buy on the broader panel. Twenty-three sell-side firms cover the name with 10 bullish, 11 neutral, and two bearish. The average price target of $82.39 implies roughly 11% upside from Tuesday's level, and B of A Securities' Curtis Nagle sits near the high at $105 with a Buy rating on August 20.
Risks: The panel is far from uniform. Wells Fargo's Ken Gawrelski maintained Underweight at $47 in February, and UBS's Chris Kuntarich trimmed his target to $53 from $74 on February 20 while maintaining Neutral. Gross-merchandise-sales trajectory, buyer-frequency initiatives execution, and competitive dynamics from Amazon Handmade and Temu all remain factors to monitor.
ResMed (RMD) – RBC Turns Bullish on Sleep-Apnea Franchise
Sleep-apnea and respiratory-care leader ResMed was upgraded from Sector Perform to Outperform on Tuesday by RBC Capital analyst Craig Wong-Pan, who raised his price target to $262 from $244. The thesis focuses on flow-generator device growth remaining structurally supported by expanded diagnosis rates, mask-and-accessory resupply revenue extending recurring-revenue durability, and GLP-1 competitive concerns proving overblown as clinical evidence links weight-loss to reduced but persistent sleep-apnea prevalence.
Shares traded near $232.69 during Tuesday's session, up about 4.35% on the upgrade catalyst, giving ResMed a market capitalization near $34 billion. The 52-week range of $180.27 to $284.87 shows the stock trading in the middle of the year's range. The trailing price-to-earnings multiple sits at 22.38, and the dividend yield sits near 1%.
Consensus reads buy on the broader panel. Ten sell-side firms cover the name with three bullish and seven neutral. The average price target of $241.90 implies modest upside from Tuesday's level, and Keybanc's Brett Fishbin sits near the high at $267 with an Overweight rating on August 31.
Risks: The panel remains cautious in aggregate. Wells Fargo's Nathan Treybeck trimmed his target to $227 from $270 on May 1 while maintaining Equal-Weight, and RBC's own prior Sector Perform stance held until this week. GLP-1 competitive dynamics, mask-and-accessory resupply rates, and flow-generator device growth pace all remain factors to monitor.
Enbridge (ENB) – Dual Upgrades on Pipeline Franchise
Canadian energy-infrastructure and pipeline leader Enbridge drew two upgrades on Tuesday: BMO Capital moved from Market Perform to Outperform with a $79.50 price target, and National Bank lifted the stock from Sector Perform to Outperform. The thesis focuses on secured-capital-program execution extending contracted-cash-flow visibility, Ingleside Energy Center and U.S. gas-utility segment adding accretive growth beyond the Canadian mainline, and dividend growth remaining well-covered by distributable cash flow.
Shares traded near $48.40 during Tuesday's session, up about 0.50%, giving Enbridge a market capitalization near $106 billion. The 52-week range of $45.03 to $58.45 shows the stock trading near the low end of the year's range. The trailing price-to-earnings multiple sits at 22.45, and the dividend yield sits near 6%.
Consensus reads strong buy from RBC Capital's Maurice Choy, who maintained Outperform at $84 on August 3 (raised from $79). Broader coverage is thin but bullish where present.
Risks: Not all commentary is uniformly aligned. Prior BMO and National Bank coverage held at Market Perform and Sector Perform respectively for extended periods. Canadian regulatory approval pace, U.S. gas-utility segment integration, and dividend-growth sustainability all remain factors to monitor.
Found this helpful? Share it with others.